axitinib

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

By Sharon Deveson Kell|2023-01-12T15:18:26+00:0012 Jan 2023|Drug treatments|

A recent paper published in The Oncologist has shown that [...]

Read More

Comments Off on Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

• 

Does neoadjuvant therapy improve outcomes in localised kidney cancer?

By Sharon Deveson Kell|2023-01-12T09:51:58+00:0012 Jan 2023|Drug treatments|

At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]

Read More

Comments Off on Does neoadjuvant therapy improve outcomes in localised kidney cancer?

• 

Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

By Sharon Deveson Kell|2022-10-27T08:20:36+00:0027 Oct 2022|Drug treatments|

When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]

Read More

Comments Off on Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

• 

C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer

By Sharon Deveson Kell|2022-10-03T09:02:32+00:003 Oct 2022|Drug treatments, Uncategorized|

  A biomarker is a biological molecule found in blood, other body [...]

Read More

Comments Off on C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer

• 

Neoadjuvant axitinib may reduce venous tumour thrombus in kidney cancer

By Sharon Deveson Kell|2022-08-25T07:19:22+00:0025 Aug 2022|Drug treatments|

Neoadjuvant treatment is medication that is given before surgery to [...]

Read More

Comments Off on Neoadjuvant axitinib may reduce venous tumour thrombus in kidney cancer

• 

Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours

By Sharon Deveson Kell|2022-05-17T07:58:26+00:0017 May 2022|Drug treatments|

Just over half of the patients from a phase 2 [...]

Read More

Comments Off on Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours

• 

ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer

By Sharon Deveson Kell|2022-02-24T08:25:41+00:0023 Feb 2022|Drug treatments|

Results from the NeoAvAx clinical trial were presented at the [...]

Read More

Comments Off on ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer

• 

ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer

By Robert|2021-07-07T12:53:37+00:008 Jun 2021|Drug treatments|

The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus [...]

Read More

Comments Off on ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer

• 

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

By Sophie|2021-03-09T14:39:04+00:002 Mar 2021|Drug treatments|

This Practice Update interview with Dr Monty Pal from City [...]

Read More

Comments Off on Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer